Treatment Clinical Trials for Chronic Lymphocytic Leukemia

Clinical trials are research studies that involve people. The clinical trials on this list are for chronic lymphocytic leukemia treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 151-161 of 161
< Previous 1 ... 5 6 7

  • Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

    Background: B-cell lymphoma is a cancer of certain white blood cells (called lymphocytes). These cells are found in lymph nodes. The cancer can cause enlargement of the lymph nodes leading to pain and discomfort. Swollen lymph nodes can also press on nearby organs such as liver and kidneys which can affect normal functioning of the organs. Researchers think that a new combination of drugs may be able to help. Objective: To find out if it is safe to give the combination of Magrolimab, Obinutuzumab and Venetoclax to people with B-cell lymphomas. Eligibility: Adults age 18 and older with an indolent B-cell lymphoma whose disease has returned or progressed after other treatment. Indolent B-cell lymphoma for this protocol is defined as having either follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia / small lymphocytic lymphoma or marginal zone lymphoma. Design: Participants will be screened under a separate protocol. Participants will have 28-day 'cycles' of treatment. They will take Venetoclax by mouth daily. They will get Obinutuzumab and Magrolimab by intravenous (IV) infusion. Treatment will last for about 8 months. They may be able to have more cycles of treatment if their cancer is responding well. Participants will have physical exams, medical histories, and medicine reviews. Data about how they function in their daily activities will be obtained. They will have blood and urine tests. They may have bone marrow tests. Participants will have imaging scans. These will include computed tomography (CT) and / or magnetic resonance imaging (MRI) scans and positron emission tomography (PET) scans. Participants may give a cheek swab or saliva sample. They may give tumor tissue and bone marrow samples. These samples may be used for gene testing. Participants will have a follow-up visit about 30 days after treatment ends. Then they will have visits every 3 months for the first 2 years, every 6 months for the next 3 years, and then yearly after that.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

  • FT819 in Subjects With B-cell Malignancies

    This is a Phase I dose-finding study of FT819 as monotherapy and in combination with IL-2 in subjects with relapsed / refractory B-cell Lymphoma, Chronic Lymphocytic Leukemia and Precursor B-cell Acute Lymphoblastic Leukemia. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
    Location: 2 locations

  • Ibrutinib for the Treatment of Patients with B-Cell Malignancies Who Are Infected with Coronavirus Disease 2019 (COVID-19)

    This phase II trial studies the effect of ibrutinib in treating patients with B-cell malignancies who are infected with the virus responsible for coronavirus disease 2019 (COVID-19). Ibrutinib blocks a protein called Bruton’s tyrosine kinase (BTK), which may help keep cancer cells from growing. The goals of this study are twofold: a) to conduct a prospective observational cohort study to determine the risk of hospitalization among patients on ibrutinib therapy with COVID-19 infection in the outpatient setting (ibrutinib may be continued or not per investigator’s choice); and b) to randomly assign hospitalized patients who are on ibrutinib therapy for a hematologic malignancy and who develop COVID-19 infection to either stop ibrutinib or continue with the drug.
    Location: Mayo Clinic in Rochester, Rochester, Minnesota

  • Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients with Hematological Malignancies Treated with Alemtuzumab

    This phase II trial studies how well letermovir works for the prevention of cytomegalovirus reactivation in patients with hematological malignancies treated with alemtuzumab. Patients receiving treatment with alemtuzumab may experience cytomegalovirus reactivation. Letermovir may block cytomegalovirus replication and prevent infection.
    Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio

  • Modified Immune Cells (CD19-CD22 CAR T cells) in Treating Patients with Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

    This phase I / II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin’s lymphoma that has come back (recurrent) or does not respond to treatment (refractory). T-cells are collected from the patient and genetic materials called “chimeric antigen receptors (CAR)” are transferred to the collected T-cells. The CAR T-cells are then infused back to the patient's body. Giving CD19- CD22 CAR T cells after chemotherapy may help to control the disease.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Bendamustine and Rituximab in Combination with Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    This trial studies how well bendamustine and rituximab in combination with copanlisib work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Drugs used in chemotherapy, such as bendamustine and rituximab, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Copanlisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving bendamustine and rituximab with copanlisib may work better than bendamustine and rituximab alone in treating chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington

  • Abbreviated Mycophenolate Mofetil and Sargramostim after Stem Cell Transplant in Treating Patients with High Risk or Recurrent Hematological Malignancies

    This randomized phase II trial studies how well a shortened course of treatment with mycophenolate mofetil after stem cell transplant works when given with sargramostim in treating patients with a cancer that affects the blood or bone marrow (hematological malignancy), and is at high risk for returning or came back after previous treatment (recurrent). Graft versus host disease (GVHD) is a condition that may occur after transplant, in which the stem cells that are transplanted from a donor (the "graft") attack the normal cells of the patient (the “host”). Mycophenolate mofetil is used to help prevent GVHD after transplants. Giving mycophenolate mofetil for a shorter period of time may help the transplanted cells engraft with the patient's body more quickly, which may help the patient recover after the transplant. After transplants, colony-stimulating factors, such as filgrastim, are also given to help keep the bone marrow working to fight infections until it can recover from the transplant. Sargramostim may be a more effective treatment for supporting the bone marrow function than standard treatment with filgrastim. It is not yet known whether giving abbreviated treatment with mycophenolate mofetil and sargramostim is more effective than longer treatment given with filgrastim in treating patients with high risk or recurrent hematological malignancies after transplant.
    Location: Virginia Commonwealth University / Massey Cancer Center, Richmond, Virginia

  • Clinical Study of Relapsed / Refractory Chronic Lymphocytic Leukemia (CLL)

    This is an open-label, Phase I / Ib trial with a dose escalation phase, followed by a dose extension phase. The objective of the dose escalation phase is to evaluate the pharmacokinetics (PK) and MTD of P1446A-05 in relapsed / refractory CLL and the objective of the dose extension phase is to evaluate the safety, efficacy and pharmacodynamics of P1446A-05 in 14 patients at the MTD level.
    Location: See Clinical

  • Pyrimethamine in Treating Patients with Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or T-Cell Large Granular Lymphocyte Leukemia

    This phase I / II trial studies the best dose of pyrimethamine and to see how well it works in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or T-cell large granular lymphocyte leukemia that has returned (relapsed). Pyrimethamine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 2 locations

  • Cladribine, Cyclophosphamide, and Rituximab for the Primary Treatment of Macroglobulinemic Lymphoma

    This phase I trial studies how well cladribine, cyclophosphamide, and rituximab work for the primary treatment of macroglobulinemic lymphoma. Drugs used in chemotherapy, such as cladribine and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with rituximab, may induce changes in body’s immune system and may interfere with the ability of cancer cells to grow and spread. Giving cladribine, cyclophosphamide, and rituximab may work better in shrinking lymphoma cells compared to each drug by itself.
    Location: M D Anderson Cancer Center, Houston, Texas

  • T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

    Background: CD19 and CD20 are often found on certain cancer cells. Researchers think that a person s T cells can be modified in a lab to kill cells that have CD19 and CD20 on the surface. Objective: To see if it is safe to give anti-CD19 and anti-CD20 CAR T cells to people with a B cell cancer or Hodgkin lymphoma. Eligibility: People ages 18 and older with a B cell cancer or Hodgkin lymphoma that has not been controlled with standard therapies Design: Participants will be screened under protocol 01C0129 with: Medical history Physical exam Blood and heart tests Bone marrow biopsy: A needle is inserted into the participant s hip bone to remove a small amount of marrow. Scans Participants will have apheresis: Blood will be removed through a vein. The blood with circulate through a machine that removes the T cells. The rest of the blood will be returned to the participant. Once a day for 3 days before they get the T cells, participants will receive chemotherapy through a vein. Participants will receive the T cells through a vein. They will stay in the hospital for at least 9 days. Participants may have a lumbar puncture: A needle will remove fluid from the spinal cord. Participants may have a tumor biopsy. Participants will repeat the screening tests throughout the study. Participants will have follow-up visits 2 weeks after infusion; monthly for 4 months; at 6, 9, and 12 months; every 6 months for 3 years; and then annually for 5 years. Participants will then be contacted annually for 15 years.
    Location: National Institutes of Health Clinical Center, Bethesda, Maryland

< Previous 1 ... 5 6 7